Genprex (GNPX) Stock Price, News & Analysis

Company Overview

Genprex, Inc. is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes. This preclinical program seeks to deliver genes that support insulin production and glucose regulation, laying the groundwork for future clinical development in metabolic diseases. By leveraging its gene delivery platform, the company aims to expand its pipeline into other oncology and metabolic indications over time.

Headquartered in Austin, Texas, Genprex operates under a management team with deep experience in gene therapy research and biopharmaceutical development. The company collaborates with leading academic and clinical research centers to conduct its studies, ensuring rigorous trial design and patient enrollment. Through these partnerships, Genprex seeks to translate cutting-edge genetic science into transformative therapies for patients with high-unmet medical needs.

Key Stats

• Today's Range: $0.20 to $0.26
• 50-Day Range: $0.14 to $0.30
• 52-Week Range: $0.14 to $3.97
• Volume: 12.35 million shs
• Average Volume: 5.26 million shs
• Market Capitalization: $8.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Genprex Stock Analysis - MarketRank™

Genprex scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Genprex.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Genprex are expected to grow in the coming year, from ($5.70) to ($2.71) per share.

Price to Book Value per Share Ratio

Genprex has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.92% of the float of Genprex has been sold short.

Short Interest Ratio / Days to Cover

Genprex has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genprex has recently increased by 40.88%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genprex does not currently pay a dividend.

Dividend Growth

Genprex does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.78

Percentage of Shares Shorted

5.92% of the float of Genprex has been sold short.

Short Interest Ratio / Days to Cover

Genprex has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genprex has recently increased by 40.88%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Genprex this week, compared to 1 article on an average week.

Search Interest

6 people have searched for GNPX on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Genprex to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genprex insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.44% of the stock of Genprex is held by insiders.

Percentage Held by Institutions

Only 14.05% of the stock of Genprex is held by institutions.

GNPX Stock Analysis - Frequently Asked Questions

How have GNPX shares performed this year?

Genprex's stock was trading at $0.8516 at the beginning of 2025. Since then, GNPX stock has decreased by 70.6% and is now trading at $0.2501.

How were Genprex's earnings last quarter?

Genprex (NASDAQ:GNPX) released its quarterly earnings data on Thursday, August, 14th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.54.

When did Genprex's stock split?

Genprex shares reverse split on Friday, February 2nd 2024.The 1-40 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Genprex?

Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Genprex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genprex investors own include Waste Connections (WCN), Voyager Therapeutics (VYGR), AU Optronics (AUOTY), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/10/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GNPX
• CIK: 1595248
• Web: www.genprex.com
• Phone: (877) 774-4679
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.11 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -809.27%
• Return on Assets: -386.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.84
• Quick Ratio: 0.84

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.15 per share
• Price / Book: 1.65

Miscellaneous

• Outstanding Shares: 33,467,000
• Free Float: 33,320,000
• Market Cap: $8.30 million
• Optionable: No Data
• Beta: -0.65